Inhibikase Therapeutics (IKT) versus Its Rivals Head to Head Review

Inhibikase Therapeutics (NASDAQ:IKT) is one of 896 public companies in the “Pharmaceuticals” industry, but how does it contrast to its rivals? We will compare Inhibikase Therapeutics to similar businesses based on the strength of its risk, institutional ownership, valuation, analyst recommendations, earnings, profitability and dividends.

Analyst Recommendations

This is a breakdown of current ratings and target prices for Inhibikase Therapeutics and its rivals, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Inhibikase Therapeutics	1	2	4	3	2.90
Inhibikase Therapeutics Competitors	7798	13888	25778	1037	2.41

Inhibikase Therapeutics presently has a consensus price target of $4.75, indicating a potential upside of 216.67%. As a group, “Pharmaceuticals” companies have a potential upside of 25.64%. Given Inhibikase Therapeutics’ stronger consensus rating and higher possible upside, equities research analysts plainly believe Inhibikase Therapeutics is more favorable than its rivals.

Profitability

This table compares Inhibikase Therapeutics and its rivals’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Inhibikase Therapeutics	N/A	-42.80%	-40.58%
Inhibikase Therapeutics Competitors	-2,380.38%	-217.94%	-15.54%

Volatility and Risk

Inhibikase Therapeutics has a beta of 0.94, suggesting that its share price is 6% less volatile than the S&P 500. Comparatively, Inhibikase Therapeutics’ rivals have a beta of -3.71, suggesting that their average share price is 471% less volatile than the S&P 500.

Earnings & Valuation

This table compares Inhibikase Therapeutics and its rivals gross revenue, earnings per share and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
Inhibikase Therapeutics	$260,000.00	-$48.26 million	-3.49
Inhibikase Therapeutics Competitors	$3.55 billion	$3.18 billion	555.10

Inhibikase Therapeutics’ rivals have higher revenue and earnings than Inhibikase Therapeutics. Inhibikase Therapeutics is trading at a lower price-to-earnings ratio than its rivals, indicating that it is currently more affordable than other companies in its industry.

Institutional & Insider Ownership

3.8% of Inhibikase Therapeutics shares are owned by institutional investors. Comparatively, 32.5% of shares of all “Pharmaceuticals” companies are owned by institutional investors. 7.1% of Inhibikase Therapeutics shares are owned by insiders. Comparatively, 14.2% of shares of all “Pharmaceuticals” companies are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Summary

Inhibikase Therapeutics rivals beat Inhibikase Therapeutics on 7 of the 13 factors compared.

About Inhibikase Therapeutics

Inhibikase Therapeutics, Inc., a clinical stage pharmaceutical company, develops therapeutics for Parkinson’s Disease (PD) and related disorders that arise inside and outside of the brain. The company’s product candidates include IkT-148009, a small molecule Abelson tyrosine kinase inhibitor for use in the treatment of PD, as well as gastrointestinal complications that arise as early symptoms of PD, such as swallowing, dysphagia, neurogenic constipation, and multiple system atrophy; and IkT-001Pro, a prodrug of the anti-cancer agent Imatinib that is in preclinical development to minimize gastrointestinal side effects and for the treatment of blood and stomach cancers. It is also involved in developing various research programs for other neurological diseases. The company has research and development collaborations with The Johns Hopkins University, Arizona State University, and Michigan State University, as well as Louisiana State University. Inhibikase Therapeutics, Inc. was founded in 2008 and is headquartered in Atlanta, Georgia.